UB neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication ...

Ketamine is related to the recreational drug phencyclidine (PCP). Studies have found that low doses of ketamine can quickly ...

Epilepsy is a chronic brain condition where nerve cells in the brain send incorrect signals causing seizures Heres how it ...

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...

Emerging research suggests that chronic inflammation, rather than neurotransmitter deficiencies alone, may be a major factor ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

"This data gives patients the option to benefit from esketamine treatment either with or without an antidepressant," said ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 ...

Repetitive transcranial magnetic stimulation offers rapid depression relief for patients unresponsive to conventional ...

The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to ...